Colon Targeting Drug Delivery Market Report 2026

The colon targeting drug delivery market size has grown strongly in recent years. It will grow from $1.5 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limitations of conventional drug delivery, need for localized treatment, rising prevalence of gastrointestinal disorders, advancements in oral formulation science, demand for reduced systemic side effects.

The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of colorectal cancer therapies, innovation in microbially triggered systems, increasing pharmaceutical R&D investments, demand for patient-centric drug delivery solutions. Major trends in the forecast period include increasing focus on targeted drug delivery systems, growing use of pH-sensitive and time-dependent technologies, rising adoption for inflammatory bowel disease treatment, expansion of colon-specific cancer therapies, development of advanced oral dosage forms.

The increasing prevalence of gastrointestinal diseases is expected to drive the growth of the colon-targeting drug delivery market in the coming years. Gastrointestinal diseases are disorders that affect the digestive tract, including the stomach, intestines, and related organs. Their rising prevalence is primarily due to unhealthy dietary habits, such as excessive consumption of processed foods and low fiber intake, which disrupt gut health and digestion. Colon-targeting drug delivery systems are used to deliver medication precisely to the site of inflammation or infection, improving therapeutic effectiveness while minimizing systemic side effects. For example, in June 2023, Crohn's and Colitis Canada, a nonprofit organization, reported that the number of individuals affected by inflammatory bowel disease is projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). Consequently, the increasing prevalence of gastrointestinal diseases is boosting growth in the colon-targeting drug delivery market.

Leading companies in the colon-targeting drug delivery market are focusing on developing innovative solutions, such as functional oral dosage forms, to improve targeted drug release, enhance therapeutic efficacy, and reduce side effects. Functional oral dosage forms are designed to protect active pharmaceutical ingredients from degradation in the upper gastrointestinal tract and ensure controlled release specifically in the colon. For example, in September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology for targeted oral drug delivery to the colon. This advanced system uses pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring the active ingredient reaches the colon intact. By enabling oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional supports the development of patient-friendly therapies and broadens treatment options for chronic gastrointestinal disorders with improved precision and reduced systemic exposure.

In October 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Telavant Holding Inc. for $7.1 billion. This acquisition strengthens Roche’s colon-targeting drug delivery portfolio by adding RVT-3101, advancing its capabilities in treating inflammatory bowel diseases. Telavant Holding Inc. is a US-based biopharmaceutical company specializing in developing therapies for gastrointestinal disorders.

Major companies operating in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., Tharimmune Inc.

North America was the largest region in the colon targeting drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colon targeting drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the colon targeting drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the colon targeting drug delivery market by increasing the cost of imported polymers, excipients, coating materials, and specialized formulation inputs used in colon-specific systems. These impacts are most evident in advanced dosage form and nanoparticle-based delivery segments, particularly in North America and Europe where raw material sourcing is globally diversified. Asia-Pacific manufacturers have experienced cost volatility due to trade dependencies. However, tariffs have supported domestic production of drug delivery excipients and localized formulation development.

The colon targeting drug delivery market research report is one of a series of new reports that provides colon targeting drug delivery market statistics, including colon targeting drug delivery industry global market size, regional shares, competitors with a colon targeting drug delivery market share, detailed colon targeting drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the colon targeting drug delivery industry. This colon targeting drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Colon-targeted drug delivery is a specialized system designed to release therapeutic agents specifically in the colon, improving treatment effectiveness for local conditions such as inflammatory bowel disease and colorectal cancer, while minimizing systemic side effects and enhancing patient compliance.

The main dosage forms in colon-targeted drug delivery include tablets, capsules, microspheres, nanoparticles, and others. Tablets are solid, compressed forms intended for oral use and are often coated with materials that prevent dissolution in the stomach or small intestine, allowing the drug to be released directly in the colon. This system employs technologies such as pH-sensitive systems, time-dependent systems, microbially triggered systems, and pressure-controlled systems. It is applied in treating conditions such as inflammatory bowel disease, colorectal cancer, infectious diseases, and more, and is primarily used by hospitals, clinics, research institutes, and other end users.

The colon targeting drug delivery market includes revenues earned by entities by providing services such as formulation development, preformulation studies, drug delivery technology licensing, coating and encapsulation services, and in-vitro release testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.